retatrutide type 2 diabetes phase 2 weight loss 2024 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care π¨Breaking: Retatrutide's first Phase 3
Description
For individuals with existing heart conditions, this aspect of the safety profile will require careful consideration once the medication becomes available
PMCID: PMC8235588
thyroid cancer or hyperthyroidism, gastroparesis, pancreatic cancer or pancreatitis, MEN2 syndrome, or inflammatory bowel disease)
These situations can impact the bodys insulin requirements and hence diabetes control, making it crucial to closely monitor for changes
Summary of Revisions: Standards of Medical Care in Diabetes2020
